Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;66(12):1625-56.
doi: 10.2165/00003495-200666120-00012.

Orlistat: a review of its use in the management of obesity

Affiliations
Review

Orlistat: a review of its use in the management of obesity

Sheridan Henness et al. Drugs. 2006.

Abstract

Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data have shown that orlistat is also effective as a component of weight management strategies in obese adolescents. In addition to its well established efficacy in achieving modest weight loss, orlistat has been shown to improve glycaemic parameters in obese adults with type 2 diabetes mellitus as well as some features of the metabolic syndrome. Orlistat is generally well tolerated. Thus, orlistat is an option for the treatment of obese patients with or without type 2 diabetes and also has a role in the management of obese patients with the metabolic syndrome, associated comorbidities or concomitant disorders.

PubMed Disclaimer

References

    1. Endocr Pract. 2006 Jan-Feb;12(1):18-28 - PubMed
    1. JAMA. 1999 Jan 20;281(3):235-42 - PubMed
    1. Diabetes Care. 1992 Jul;15(7):820-5 - PubMed
    1. J Clin Pharmacol. 1995 May;35(5):521-5 - PubMed
    1. J Clin Pharmacol. 1996 Jul;36(7):659-66 - PubMed

Publication types

MeSH terms

LinkOut - more resources